This startup develops a novel anti-depressant drug using naturally sourced psychedelics derived from botanic extracts of mushrooms and root bark, produced through an agro-medical bioreactor platform. Their approach enables pharmaceutical companies to enhance existing anti-depressant treatments with micro-dosing, providing a daily dose that avoids psychedelic effects while improving patient compliance.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antidepressant treatments often suffer from limitations such as delayed therapeutic effects, side effects, and variable patient compliance, hindering effective management of mental health disorders. Many patients do not respond adequately to existing therapies, creating a need for novel treatment options.
Solution
PsyRx is developing a pharmaceutical-grade antidepressant that combines a selective serotonin reuptake inhibitor (SSRI) with a microdose of ibogaine, a psychoactive compound derived from the iboga tree. This fixed-dose combination aims to enhance neuronal plasticity without inducing psychoactive effects, allowing for a once-daily oral dosage form that does not require supervision or disrupt daily life. The company's approach leverages the therapeutic potential of psychedelics while mitigating the risks associated with hallucinogenic effects. By combining established SSRIs with microdoses of ibogaine, PsyRx intends to improve treatment outcomes and patient adherence in managing depression and other mental health conditions.
Target Audience
The primary target audience includes pharmaceutical companies seeking to enhance their existing antidepressant product lines, as well as psychiatrists and general practitioners looking for improved treatment options for patients with depression and other mental health disorders.
Features
- Fixed-dose combination of an SSRI and a microdose of ibogaine
- Oral dosage form for convenient, once-daily administration
- Designed to avoid psychoactive effects, ensuring patient safety and compliance
- Aims to enhance neuronal plasticity for improved antidepressant efficacy
- Utilizes botanically-sourced ibogaine, extracted from the root bark of the iboga tree